AP2005003292A0 - Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof - Google Patents

Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Info

Publication number
AP2005003292A0
AP2005003292A0 AP2005003292A AP2005003292A AP2005003292A0 AP 2005003292 A0 AP2005003292 A0 AP 2005003292A0 AP 2005003292 A AP2005003292 A AP 2005003292A AP 2005003292 A AP2005003292 A AP 2005003292A AP 2005003292 A0 AP2005003292 A0 AP 2005003292A0
Authority
AP
ARIPO
Prior art keywords
cystic fibrosis
protein inhibitors
fibrosis transmembrane
conductance regulator
transmembrane conductance
Prior art date
Application number
AP2005003292A
Other languages
English (en)
Inventor
Alan Verkman
Tonghui Ma
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/262,573 external-priority patent/US20040063695A1/en
Application filed by Univ California filed Critical Univ California
Publication of AP2005003292A0 publication Critical patent/AP2005003292A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2005003292A 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof AP2005003292A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/262,573 US20040063695A1 (en) 2002-09-30 2002-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US48025303P 2003-06-20 2003-06-20
PCT/US2003/031005 WO2004028480A2 (fr) 2002-09-30 2003-09-30 Inhibiteurs de proteine regulant la permeabilite transmembranaire de la fibrose kystique (cftr) et uitlisations

Publications (1)

Publication Number Publication Date
AP2005003292A0 true AP2005003292A0 (en) 2005-06-30

Family

ID=32044981

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003292A AP2005003292A0 (en) 2002-09-30 2003-09-30 Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof

Country Status (13)

Country Link
EP (1) EP1549321A4 (fr)
JP (1) JP4977319B2 (fr)
KR (1) KR20050061501A (fr)
CN (1) CN100356922C (fr)
AP (1) AP2005003292A0 (fr)
AU (1) AU2003277162C1 (fr)
BR (1) BR0314943A (fr)
CA (1) CA2500498C (fr)
EA (1) EA009847B1 (fr)
MX (1) MXPA05003366A (fr)
NZ (1) NZ538809A (fr)
PL (1) PL376147A1 (fr)
WO (1) WO2004028480A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
PT2007756E (pt) 2006-04-07 2015-11-02 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008121877A2 (fr) 2007-04-02 2008-10-09 Institute For Oneworld Health Composés inhibiteurs de cftr et leurs utilisations
CA2696298C (fr) * 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique
NZ598941A (en) 2007-11-16 2013-06-28 Vertex Pharma Isoquinoline modulators of ATP-Binding Cassette transporters
PL2225230T3 (pl) 2007-12-07 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
EP2279029A2 (fr) * 2008-03-25 2011-02-02 The Regents of the University of California Inhibiteurs à petite molécule soluble dans l eau du régulateur de conductance transmembranaire de fibrose kystique
ES2552990T3 (es) 2008-03-31 2015-12-03 Vertex Pharmaceuticals Incorporated Derivados de piridilo como moduladores del CFTR
US8207205B2 (en) 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131951A2 (fr) 2008-04-21 2009-10-29 Institute For Oneworld Health Composés, compositions et procédés comprenant des dérivés isoxazole
EP2341776A4 (fr) * 2008-09-19 2012-05-30 Inst Oneworld Health Composés, compositions et procédés comprenant des dérivés d'imidazole et de triazole
US8343976B2 (en) 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
EP2490696A1 (fr) * 2009-10-20 2012-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement des troubles de l'homéostasie du glucose
WO2011119984A1 (fr) 2010-03-25 2011-09-29 Vertex Pharmaceuticals Incorporated Formes solides de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RS54783B1 (sr) 2010-04-07 2016-10-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzoeve kiseline
ES2604480T5 (es) 2010-04-07 2020-03-17 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
AU2011242712B2 (en) 2010-04-22 2016-01-28 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医科大学附属北京同仁医院 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用
JP6014816B2 (ja) 2011-05-10 2016-10-26 国立大学法人神戸大学 Ｒａｓ機能阻害作用を有するチオキソチアゾリジン誘導体
AU2012335714B2 (en) 2011-11-08 2017-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
PL2806859T3 (pl) 2012-01-25 2019-11-29 Vertex Pharma Formulacje kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5- ilo)cyklopropanokarboksyamido)-3-metylopirydyn-2-ylo)benzoesowego
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
CN111671751A (zh) 2012-11-02 2020-09-18 沃泰克斯药物股份有限公司 用于治疗cftr介导的疾病的药物组合物
FR2999191B1 (fr) 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
IL303422A (en) 2014-04-15 2023-08-01 Vertex Pharma Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators
MX2017004543A (es) 2014-10-06 2017-10-04 Vertex Pharma Moduladores de regulador de conductancia transmembranal de fibrosis quística.
CN104398509B (zh) * 2014-11-13 2017-01-11 四川大学华西第二医院 CFTR抑制剂CFTRinh-172在制备防治白血病细胞介导的疾病的药物中的应用
CN104788423B (zh) * 2015-03-13 2016-10-26 成都理工大学 一种新的囊性纤维化跨膜传导调节因子抑制剂
BR112018012927A2 (pt) 2015-12-24 2018-12-11 Univ California reguladores cftr e métodos de uso dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9010041B (en) * 1989-12-21 1992-08-26 Lilly Co Eli Compounds for treating inflammatory bowel disease
AU1090795A (en) * 1993-11-12 1995-05-29 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
BR9913157A (pt) * 1998-08-21 2001-05-15 Viropharma Inc Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
US6484397B1 (en) * 2000-07-11 2002-11-26 Corning Incorporated Method of assembling a catalytic converter for use in an internal combustion engine
US20020052396A1 (en) * 2001-04-23 2002-05-02 Bailey Thomas R. Compounds, compositions and methods for treating or preventing viral infections and associated diseases

Also Published As

Publication number Publication date
WO2004028480A3 (fr) 2004-07-01
CA2500498C (fr) 2012-08-21
KR20050061501A (ko) 2005-06-22
AU2003277162B2 (en) 2009-07-16
WO2004028480A2 (fr) 2004-04-08
AU2003277162A1 (en) 2004-04-19
CA2500498A1 (fr) 2004-04-08
CN100356922C (zh) 2007-12-26
EA009847B1 (ru) 2008-04-28
BR0314943A (pt) 2005-08-02
AU2003277162C1 (en) 2009-12-24
CN1684686A (zh) 2005-10-19
JP2006503853A (ja) 2006-02-02
NZ538809A (en) 2008-06-30
EP1549321A4 (fr) 2007-05-23
EP1549321A2 (fr) 2005-07-06
JP4977319B2 (ja) 2012-07-18
EA200500583A1 (ru) 2005-12-29
MXPA05003366A (es) 2005-10-05
PL376147A1 (en) 2005-12-27

Similar Documents

Publication Publication Date Title
AP2005003292A0 (en) Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
EP1495128A4 (fr) Expression proteinique amelioree dans bacillus
PL375447A1 (en) Protein kinase inhibitors and uses thereof
EP1552002A4 (fr) Molecules toxine-aptamere et procedes d'utilisation correspondants
AU2003270341A1 (en) Modified asialo-interferons and uses thereof
HUP0301063A3 (en) Benzoic-acid isononylesters and applying them
AU2003280084A1 (en) Protein arrays and uses thereof
AUPS238502A0 (en) Cystic echinococcosis protein and uses therefor
AU2003268023A8 (en) Protein modification and maintenance molecules
AU2002348834A8 (en) Method and system providing user mobility in a mobile-ip-network by means of a personal ip address
AU2003239871A8 (en) Protein modification and maintenance molecules
AU2003301112A1 (en) Hand and fingernail cleaning apparatus
AU2003231981A8 (en) Protein modification and maintenance molecules
EP1577322A4 (fr) Nouvelles proteines et leur utilisation
EP1541677A4 (fr) Nouvelles proteines et leur utilisation
AU2003291426A8 (en) Gp64-pseudotyped vectors and uses thereof
AU7080601A (en) Activation of the cystic fibrosis transmembrane conductance regulator chloride channel
AU2003260487A8 (en) Novel pancortin-pablo protein interactions and methods of use thereof
AU2003202650A1 (en) Cystic echinococcosis protein and uses therefor
AU2003249644A8 (en) Mutant p53 (delta126-132) protein and uses thereof
EP1549951A4 (fr) Proteines de type semaphorine et methodes d'utilisation de celles-ci
AU2003270876A8 (en) Anti-hla assay and methods
GB0228538D0 (en) Protein structure and uses thereof
AU2003265814A8 (en) Aw755252-interacting proteins and use thereof
AU2003263751A8 (en) Novel proteins and their uses